

Attorney Docket No.: ISPH-0787
Inventors: Karras and Dobie
Serial No.: 10/673,063
Filing Date: September 26, 2003
Page 2.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound ~~8~~ 5 to 50 nucleobases in length targeted to nucleobases 220 through 257, 724 through 769 or 900 through 943 of the coding region of a nucleic acid molecule encoding MyD88 (SEQ ID NO:3), wherein said compound specifically hybridizes with said nucleic acid molecule encoding MyD88 and inhibits the expression of MyD88 by at least 42%.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (currently amended): The compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: ~~14, 15, 16, 17, 18, 20, 24, 25, 26, 27, 28, 29, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 48, 50, 51, 52, 53, 54, 55, 56, 58, 59, 60, 61, 62, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 76, or 77, 82, 85, 88 or 89.~~

Claim 4 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Attorney Docket No.: ISPH-0787
Inventors: Karras and Dobie
Serial No.: 10/673,063
Filing Date: September 26, 2003
Page 3

Claim 5 (original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Claim 8 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9 (original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11 (canceled).

Claim 12 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 13 (original): The composition of claim 12 further comprising a colloidal dispersion system.

Claim 14 (original): The composition of claim 12 wherein the compound is an antisense oligonucleotide.

Attorney Docket No.: ISPH-0787
Inventors: Karras and Dobie
Serial No.: 10/673,063
Filing Date: September 26, 2003
Page 4

Claim 15 (original): A method of inhibiting the expression of MyD88 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of MyD88 is inhibited.

Claims 16-20 (canceled).